Logo

BeiGene's Kyprolis (carfilzomib) Receives NMPA's Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma

Share this

BeiGene's Kyprolis (carfilzomib) Receives NMPA's Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma

Shots:

  • The approval is based on P-III trial evaluating efficacy & safety of Kyprolis + dexamethasone in 123 patients with RRMM who have received at least 2 prior therapies- including a proteasome inhibitor & an immunomodulatory agent
  • Results: ORR (35.8%); m-PFS (5.6mos.) as assessed by IRC. Additionally- results showed that the efficacy & safety in Chinese patients who had received a median of 4 prior lines of therapy was generally consistent with that seen in the global studies
  • BeiGene got the license for Kyprolis under its collaboration with Amgen. The approval marks the first approval of the therapy in China

  Ref: BeiGene | Image: Forbes

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions